Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Asieris Pharmaceuticals Gets FDA Green Light for USP1 Inhibitor APL-2302 in Advanced Solid Tumors

Fineline Cube Oct 25, 2024

Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has announced that it...

Company Drug

Henlius Biotech Commences Global Phase III Trial for Serplulimab in First-Line Metastatic Colorectal Cancer

Fineline Cube Oct 25, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Drug

ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Dual-Target Therapy in Systemic Lupus Erythematosus

Fineline Cube Oct 25, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first...

Policy / Regulatory

China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding

Fineline Cube Oct 25, 2024

The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding...

Company Drug

Sanofi’s Dupixent Demonstrates Positive Results in Phase III Study for Chronic Urticaria

Fineline Cube Oct 25, 2024

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced the presentation of new data from...

Company Deals

3SBio Secures Exclusive Rights to Commercialize Haihe’s Paclitaxel Oral Solution in China and Hong Kong

Fineline Cube Oct 25, 2024

Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc. (HKG: 1530), two Chinese pharmaceutical companies, have...

Policy / Regulatory

China’s NMPA and Denmark’s Medicines Agency Commit to Enhanced Regulatory Cooperation

Fineline Cube Oct 25, 2024

The National Medical Products Administration (NMPA) of China and the Danish Medicines Agency have signed...

Company Deals

NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China

Fineline Cube Oct 25, 2024

NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...

Company Deals

HELP Therapeutics Receives FDA Clearance for Phase I Clinical Trial of HiCM-188 Cell Therapy

Fineline Cube Oct 25, 2024

HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that...

Company Deals

Merck Acquires Modifi Biosciences to Target DNA Repair Defects in Cancer Therapies

Fineline Cube Oct 24, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered...

Company Drug

Eli Lilly’s Alzheimer’s Drug Kisunla Secures Marketing Approval in Great Britain

Fineline Cube Oct 24, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that it has received marketing approval in...

Company Medical Device

Sino Medical Sciences Technology Secures Marketing Approval for Coronary Balloon Dilation Catheter in Morocco

Fineline Cube Oct 24, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a China-based medical device company, has announced that...

Company Drug

Gan & Lee Pharmaceuticals Initiates Phase I Clinical Trial for Biosimilar Secukinumab

Fineline Cube Oct 24, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of...

Company Drug

Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy

Fineline Cube Oct 24, 2024

Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF),...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study

Fineline Cube Oct 24, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...

Policy / Regulatory

NMPA’s Center for Drug Evaluation Issues New Guidelines for Domestic Transfer of Overseas-Produced Vaccines

Fineline Cube Oct 24, 2024

The Center for Drug Evaluation under the National Medical Products Administration (NMPA) has issued the...

Company Deals

Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004

Fineline Cube Oct 23, 2024

Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a...

Company

Sunshine Guojian Pharma Reports Q3 Revenue Growth and Advances in Clinical Trials

Fineline Cube Oct 23, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

LINDIS Biotech’s Catumaxomab Receives Positive Opinion from EMA’s COMP for Malignant Ascites Treatment

Fineline Cube Oct 23, 2024

LINDIS Biotech GmbH, a German biotechnology company, has announced that the Committee for Orphan Medicinal...

Policy / Regulatory

China’s NMPA Launches Pilot Program for Phased Manufacturing of Biological Products

Fineline Cube Oct 23, 2024

The National Medical Products Administration (NMPA) has officially released the “Pilot Work Plan for Phased...

Posts pagination

1 … 234 235 236 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.